The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...
The FDA has approved paltusotine, a selectively targeted somatostatin receptor type 2 nonpeptide agonist, for first-line treatment of certain patients with acromegaly, Crinetics Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback